Webinar Date/Time: Mon, Dec 4, 2023 11:00 AM EST
Gain critical information to make decisions in minutes. Rapidly assess the impact of cell culture conditions on mAb quality and production.
Biopharmaceutical product development is all about product knowledge, whether it be writing a regulatory submission, investigating unexpected results, or performing extended characterization. To ensure product safety and process consistency, it is critical to characterize and monitor charge variants according to regulatory and quality requirements. However, conventional approaches for these assays are time-intensive and often provide insufficient separation resolution.
In this webinar, we will discuss a new strategy to dramatically simplify charge variant characterization. Discover how you can gain multiple pieces of critical information early in process development to assess the impact of cell culture conditions on monoclonal antibody (mAb) quality and production.
Key Learning Objectives:
By attending this webinar, you will learn how to:
Who Should Attend:
Senior Director, Global Analytical Strategy & Development
FujiFilm Diosynth Biotechnologies
Greg Adams has 30 years of experience in analytical development, specializing in the mass spectrometric characterization of protein-based biopharmaceuticals. Greg has spent the majority of his career at FUJIFILM Diosynth Biotechnologies supporting the characterization and commercialization of biotherapeutic proteins. In his current role, he is responsible for strategic projects related to Fujifilm’s analytical service offerings, new analytical technologies, and industry collaborations.